

Raltegravir
Catalog No. HRP-11680


This reagent is the property of the U.S. Government.

Product Description:

Raltegravir [brand name: Isentress® (MK-0518); also referred to as raltegravir potassium] is an orally bioavailable Human Immunodeficiency Virus type 1 (HIV-1) integrase inhibitor. Inhibition of the viral integrase prevents the insertion of HIV DNA into the human DNA genome, blocking the ability of HIV-1 to replicate. Formulations containing raltegravir have been used in combination therapy in the treatment of HIV-1 infection.

Lot: 70052554
Manufacturing Date: 17MAY2022

All information provided by Biosynth® Carbosynth.
The date of analysis for the bulk material (Biosynth® Carbosynth lot FR276701601) was 17SEP2019.

Chemical Name	N-[(4-Fluorophenyl)methyl]-1,6-dihydro-5-hydroxy-1-methyl-2-[1-methyl-1-[[[(5-methyl-1,3,4-oxadiazol-2-yl)carbonyl]amino]ethyl]-6-oxo-4-pyrimidine-carboxamide, monopotassium salt
Structure	
Formula	C ₂₀ H ₂₀ FN ₆ O ₅ K
Molecular Weight	482.5
CAS Number	871038-72-1
Content per Vial	2.0 mg ± 0.3 mg
Appearance	White crystalline powder
Purity	99.4%
Loss on drying	0.1%

/Ken Crawford/
 Ken Crawford
 Lead Technical Writer, ATCC Federal Solutions

15 JUL 2022

ATCC®, on behalf of the NIH HIV Reagent Program, hereby represents and warrants that the material provided under this certificate has been subjected by the manufacturer to the tests and procedures specified and that the results described, along with any other data provided in this certificate, are true and accurate to the best of ATCC's knowledge.

ATCC® is a trademark of the American Type Culture Collection.
 You are authorized to use this product for research use only. It is not intended for human use.

